The $1,349/Month Drug Now Costs $245. Thirty-Six Million Americans Just Became Eligible.

Thirty-six million. That is the number of non-elderly Americans with employer health coverage who meet BMI criteria for GLP-1 weight loss therapy, according to a Kaiser Family Foundation analysis. As of January 2025, roughly 6 million Americans were filling GLP-1 prescriptions. That leaves a 30-million-person gap between eligible and treated. What changed in the last six months is the reason for that gap: it was price. Wegovy listed at $1,349 per month. Ozempic at roughly $1,000. Insurance coverage was sparse, prior authorization was hostile, and the compounding pharmacies filling the void operated under a temporary shortage exemption that expired in February 2025.

Three things happened in rapid succession. The FDA approved oral semaglutide 25 mg for weight loss, creating the first GLP-1 pill for obesity. Novo Nordisk reported Phase 3b results for a higher-dose injectable showing 20.7% mean body weight loss. And the TrumpRx program negotiated Medicare and Medicaid pricing to $245 per month, a 70% reduction from the wholesale acquisition cost.

Separately, each is significant. Together, they mark the transition of GLP-1 drugs from premium injectables into chronic mass-market medications. That transition changes the math for everyone: patients, insurers, employers, and the companies producing these drugs at scale.

What the Clinical Data Actually Shows

Start with the oral pill. The OASIS 4 Phase 3 trial enrolled adults with obesity or overweight with at least one weight-related comorbidity. Oral semaglutide at 25 mg daily produced 16.6% mean weight loss over 68 weeks in treatment-adherent patients, compared to 2.7% for placebo. Seventy-six percent of patients on the drug achieved at least 5% body weight loss, versus 31% on placebo. That efficacy trails the injectable formulation, but the delivery mechanism matters: a daily pill eliminates the injection barrier that keeps a substantial fraction of eligible patients from starting therapy.

Then the higher dose. The STEP UP Phase 3b trial, published in The Lancet Diabetes & Endocrinology in September 2025, tested semaglutide 7.2 mg (triple the current Wegovy dose) against the standard 2.4 mg and placebo over 72 weeks. Results at 7.2 mg: 20.7% mean body weight loss in treatment-adherent patients. At 2.4 mg: 17.5%. Placebo: 2.4%. More notably, 33.2% of patients on the higher dose lost at least 25% of their body weight, versus 16.7% at the current dose. A quarter of your body weight, gone in 72 weeks.

And the cardiovascular data keeps accumulating. The SELECT trial (n = 17,604) demonstrated that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% (hazard ratio 0.80, 95% CI 0.72-0.90, P<.001). That result earned Wegovy an expanded FDA label for cardiovascular risk reduction, making it the first obesity drug with a proven heart benefit. At 6.5% event rate versus 8.0% for placebo, that is 1.5 cardiovascular events prevented per 100 patients treated over 40 months.

The Pipeline: Seven Drugs Racing

Semaglutide is the incumbent, but the pipeline behind it is deeper than most people realize. Here is what is in development, by clinical stage and mechanism:

Drug	Company	Route	Frequency	Weight Loss	Status
Semaglutide 2.4 mg (Wegovy)	Novo Nordisk	Injection	Weekly	15-17%	Approved
Semaglutide 7.2 mg	Novo Nordisk	Injection	Weekly	20.7%	Phase 3b complete
Oral semaglutide 25 mg	Novo Nordisk	Oral	Daily	16.6%	FDA approved
Tirzepatide (Zepbound)	Eli Lilly	Injection	Weekly	20-22%	Approved
Orforglipron	Eli Lilly	Oral	Daily	11.2%	Phase 3
CagriSema	Novo Nordisk	Injection	Weekly	~20%	Phase 3
Retatrutide	Eli Lilly	Injection	Weekly	24.2%*	Phase 3
MariTide	Amgen	Injection	Monthly	TBD	Phase 3

*Phase 2 data. Phase 3 results pending.

Retatrutide deserves attention. It is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. In Phase 2 data published in NEJM, the 12 mg dose produced 24.2% mean body weight loss at 48 weeks. If that number holds in Phase 3 (the TRIUMPH trials, results expected in 2026), retatrutide would be the most effective weight loss drug ever tested. But Phase 2 numbers routinely shrink in Phase 3. Caution is appropriate.

Eli Lilly's orforglipron is the other oral contender. The ATTAIN-1b trial showed 11.2% weight loss at the 36 mg dose over 72 weeks, with a 10 cm reduction in waist circumference versus 3.1 cm for placebo. Less effective than injectable semaglutide, but it is a small-molecule pill, meaning manufacturing is simpler and cheaper than the peptide-based oral semaglutide. If Lilly can hit a lower price point, the math shifts.

Amgen's MariTide offers a different value proposition: monthly dosing instead of weekly. Amgen's MARITIME Phase 3 trial is underway. For the roughly 30% of patients who cite injection frequency as a barrier, once-a-month changes the compliance calculus.

The Price Revolution: Running the Numbers

Here is the original analysis. At the old list prices, GLP-1s for weight loss were economically indefensible for most payers. At the new prices, they are unambiguously cost-effective. The math:

Obesity increases annual direct medical costs by approximately $1,861 per person above normal-weight adults (CDC estimate, 2019 dollars). Lifetime additional medical costs for an obese individual: $92,000 to $150,000. Comorbidity-specific costs compound rapidly: type 2 diabetes adds $16,750 per year, a first cardiovascular event costs $18,953 in year one, and sleep apnea CPAP therapy runs $5,000 annually.

GLP-1 cost at the old price: $12,000 to $16,000 per year. At the new Medicare-negotiated price: $2,940 per year ($245/month). At TrumpRx program pricing: $4,200 per year ($350/month).

Cost-per-QALY is the standard metric for whether a drug is worth paying for. A 20% body weight loss restores approximately 0.05 to 0.10 quality-adjusted life years per year, depending on baseline BMI and comorbidity burden (derived from published EQ-5D utility mappings). Adding the cardiovascular benefit from SELECT (HR 0.80 for MACE, which translates to roughly 0.02-0.05 additional QALYs per year), the total QALY gain is 0.07 to 0.15 per year of treatment.

At $2,940/year for a 0.07-0.15 QALY annual gain: $19,600 to $42,000 per QALY.

At the old $16,000/year list price for the same gains: $107,000 to $229,000 per QALY.

The standard US cost-effectiveness threshold is $100,000 to $150,000 per QALY (ICER methodology). At the old prices, GLP-1s for weight loss were marginal at best, cost-ineffective at worst. At $245/month, they are roughly on par with statins for cardiovascular prevention ($20,000-$50,000/QALY), one of the most cost-effective drug classes in history.

Compare to bariatric surgery: Roux-en-Y gastric bypass costs $20,000 to $35,000 upfront, with $2,000 to $3,000 in annual follow-up for five years. Total five-year cost: $30,000 to $50,000. It achieves 25-30% sustained weight loss. GLP-1s at the new prices cost $14,700 to $21,000 over five years with comparable weight loss in the higher-dose formulations, no surgical risk (5-10% complication rate for bypass), and the ability to stop if side effects emerge. Surgery still wins on durability. GLP-1s win on reversibility and accessibility.

The Compounding Pharmacy Disruption

There is a parallel market that complicates the narrative. During the semaglutide shortage that began in early 2022, compounding pharmacies legally produced semaglutide copies under FDA section 503A exemptions. That market grew to an estimated $3 billion in annual revenue. When the FDA declared the shortage resolved in February 2025, those pharmacies lost their legal basis for production. The FDA sent warning letters to more than 50 entities in September 2025.

That crackdown created a pricing gap. Compounded semaglutide was available for $200 to $400 per month. Medicare-negotiated branded semaglutide is $245 per month. For Medicare beneficiaries, the branded price is now competitive with compounders. For the uninsured, cash-pay programs at $349 per month ($199 for the first two months) are close but still higher. Legal challenges to the compounding ban are ongoing in federal courts as of early 2026.

Limitations

This cost-per-QALY analysis uses published EQ-5D utility estimates that vary significantly across studies. The 0.05 to 0.10 QALY-per-year range is a midpoint estimate; individual gains depend heavily on baseline BMI, comorbidity count, and age at treatment initiation. Weight regain upon discontinuation is well documented. In the STEP 1 extension trial, patients who stopped semaglutide regained approximately two-thirds of lost weight within one year. GLP-1 therapy is, for most patients, a lifetime commitment, and the lifetime cost at $2,940/year over 25 years totals $73,500. Pipeline efficacy figures should be read cautiously. Retatrutide's 24.2% weight loss is Phase 2 data from a dose-ranging trial with relatively short follow-up. Phase 3 numbers are historically lower. No head-to-head trials exist between most pipeline candidates, making direct comparisons speculative. Finally, the QALY framework does not capture quality-of-life dimensions like stigma reduction, mobility improvement, or career impact that patients consistently report as primary motivators.

The Strongest Case Against Mass-Market GLP-1s

Long-term safety data beyond 2 to 4 years is thin, and that is not a trivial gap for a drug intended as lifelong therapy. The SELECT trial ran 40 months. GLP-1s for weight loss are positioned as chronic medications taken for decades. The safety profile at 72 weeks is well characterized: nausea (40-44% incidence, mostly transient), gastrointestinal events, and gallbladder-related complications. What is not well characterized is the effect of sustained GLP-1 receptor agonism over 10, 20, or 30 years.

Muscle mass loss is the most concrete concern. In studies measuring body composition, 30 to 40% of weight lost on semaglutide is lean mass, not fat. For a 45-year-old losing 20% of body weight, that could mean 12 to 16 pounds of muscle loss. Sarcopenia risk implications for older patients are unknown. Pancreatitis signals appear in post-marketing surveillance but have not reached statistical significance in controlled trials. Thyroid C-cell tumor risk, flagged in rodent studies, has not materialized in human data but lacks the decade-plus follow-up needed for confidence.

And the access equity argument cuts both ways. At $245/month, GLP-1s are affordable for Medicare beneficiaries. They remain out of reach for the 27 million uninsured Americans. Meanwhile, the compounding pharmacy crackdown removed a cheaper alternative. Whether TrumpRx pricing filters down to commercial insurance remains to be seen. If it does not, the cost-effectiveness argument applies only to a subset of the eligible population.

The Bottom Line

GLP-1 weight loss drugs are no longer a luxury product. At $245 per month on Medicare, they cost less per QALY than statins did when those drugs first entered widespread use. An oral formulation eliminates the injection barrier for millions of patients. A higher-dose injectable approaches the weight loss achieved by surgery, without the operating room. Seven drugs are in the pipeline from three companies, with mechanisms ranging from dual agonism to triple agonism to monthly antibody conjugates. For 36 million eligible Americans with employer coverage alone, the barrier to treatment just dropped from "can I afford $16,000 a year?" to "will my doctor prescribe it?" The clinical question is settled. And the economic question just flipped. What remains is whether the healthcare system, which spent a decade treating obesity as a lifestyle choice, can adapt to treating it as the chronic disease the data says it is.